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Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very
limited disease control. Very few studies have investigated salvage chemotherapy after failure of GEM or GEM-containing
chemotherapy and preclinical studies attempting to widen the therapeutic armamentarium, not including GEM, are warranted. MIA
PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines were treated with GEM, fluouracil (5-FU), docetaxel (DCT), oxaliplatin
(OXP), irinotecan (CPT-11), pemetrexed (PMX) and raltitrexed (RTX) as single agent. Pemetrexed, inducing apoptosis with IC50s
under the Cmax in the three lines tested, appeared the most effective drug as single agent. Based on these results, schedule- and
concentration-dependent drug interactions (assessed using the combination index) of PMX/GEM, PMX/DCT and PMX–CPT-11
were evaluated. The combinatory study clearly indicated the PMX and CPT-11 combination as the most active against pancreatic
cancer. To confirm the efficacy of PMX–CPT-11 combination, we extended the study to a panel of 10 pancreatic cancer cell lines
using clinically relevant concentrations (PMX 10mM; CPT-11 1mm). In eight of 10 lines, the PMX–CPT-11 treatment significantly
reduced cell recovery and increased both the subG1 and caspase 3/7 fraction. After a 5-day wash out period, an increased fraction of
subG1 and caspase3/7 persisted in PMX–CPT-11-pretreated cell lines and a significant reduction in the clonogenicity capacity was
evident. Finally, in vivo, the PMX/CPT-11 combination showed the ability to inhibit xenograft tumours growth as second-line therapy
after GEM treatment. The PMX and CPT-11 combination displays a strong schedule-independent synergistic cytotoxic activity against
pancreatic cancer, providing experimental basis for its clinical testing as salvage chemotherapy in pancreatic cancer patients.
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Until a decade ago, the use of chemotherapy in pancreatic cancer
was believed to have no role in the routine treatment of patients
with advanced disease (Lionetto et al, 1995). To date, some options
are available for first-line treatment (Burris et al, 1997; Reni et al,
2005). Single-agent fluorouracil (5-FU) results in tumour response
rates of 7% or less (Cullinan et al, 1990; Burris et al, 1997).
Combination chemotherapy with 5-FU has resulted in increased
toxicity without higher efficacy (Schnall and Macdonald, 1996;
Ducreux et al, 2002; Maisey et al, 2002; Beger et al, 2003).
Gemcitabine (GEM) in weekly infusions has been shown to be
superior to bolus 5-FU as monotherapy for advanced disease in a
randomised phase III study and was licensed for treatment of
advanced pancreatic cancer (Burris et al, 1997). Also a compre-
hensive experience reported in a large, multicentre, open-label
study that enrolled more than 3000 patients on a compassionate-
need basis documented single-agent GEM to be reasonably safe
and to offer a median overall survival of 4.8 months (Storniolo
et al, 1999). So GEM is currently regarded as the standard
treatment for advanced disease, and has led to an objective
response in 4–26% of patients and a 1-year overall survival of 17–
28% of patients in phase III trials (Burris et al, 1997; Bramhall et al,
2001; Berlin et al, 2002; Bramhall et al, 2002; Heinemann, 2002;
Moore et al, 2003; Rocha Lima et al, 2004; Van Cutsem et al, 2004;
Reni et al, 2005).
Despite the fact that randomised studies have suggested that
chemotherapy is superior to best supportive care in prolonging
survival and improving symptoms in patients with advanced
disease, standard single-agent GEM yields a marginal impact on
disease outcome. Several attempts to improve the efficacy of GEM
in advanced pancreatic adenocarcinoma by addition of a second
cytotoxic agent or other drugs to a standard dose and schedule of
GEM have not shown a significant survival advantage (Burris et al,
1997; Bramhall et al, 2001; Berlin et al, 2002; Bramhall et al, 2002;
Heinemann, 2002; Moore et al, 2003; Rocha Lima et al, 2004;
Van Cutsem et al, 2004; Mishra et al, 2005; Reni et al, 2005;
Stathopoulos et al, 2006). GEM-based chemotherapy yields a very
limited disease control, and progression usually occurs within a
few months after first-line treatment starts. Median progression-
free survival with single-agent GEM is approximately 3 months
and less than 15% of patients are progression free at 6 months
from diagnosis (Burris et al, 1997; Bramhall et al, 2001; Berlin et al,
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s2002; Bramhall et al, 2002; Heinemann, 2002; Moore et al, 2003;
Rocha Lima et al, 2004; Van Cutsem et al, 2004; Reni et al, 2005).
In spite of progressive disease, about half of the patients maintain
a good performance status and are willing to undergo further
treatment. So far very few studies have investigated salvage
chemotherapy after failure of GEM or GEM-containing chemother-
apy (Oettle et al, 2000; Ulrich-Pur et al, 2003; Cantore et al, 2004;
Milella et al, 2004; Reni et al, 2004). As no standard therapeutic
option exists and scarce information on the impact on outcome of
salvage therapy is available from the literature, preclinical studies
attempting to widen the therapeutic armamentarium, not including
GEM, are warranted.
The present study was performed in pancreatic cancer lines to
identify GEM-free combination of drugs. The PMX and CPT-11
combination showed a strong schedule-independent synergistic
cytotoxic activity against pancreatic cancer, providing experi-
mental basis for its clinical testing as salvage chemotherapy in
pancreatic cancer patients.
MATERIALS AND METHODS
Drug and chemical
GEM and PMX were from Eli Lilly (Indianapolis, IN, USA), RTX
was from AstraZeneca (Basiglio, Italy), OXP from Sanofi
Synthelabo (Milan, Italy), DCT and CPT-11 from Aventis (Milan,
Italy), 5-FU from Teva Pharma Italia (Milan, Italy). Drugs were
dissolved in sterile distilled water and diluted in culture medium
immediately before use.
Drug pharamacokinetics
The data on the pharmacokinetics of the drugs (Cmax) in human
were obtained by the revision of the earlier publications
(Abbruzzese et al, 1991; Burris et al, 1993; Extra et al, 1993;
Pazdur et al, 1993; Rothenberg et al, 1993; Clarke et al, 1996;
Chabot, 1997; Hui and Reitz, 1997; Beale et al, 1998; Gamelin et al,
1998; Judson et al, 1998; O’Dwyer et al, 1999; Rinaldi, 1999; Culy
et al, 2000; Jodrell et al, 2001).
Cell culture
Pancreatic cancer cell lines MIA PaCa2, CFPAC-1, HS766T, T3M4,
A818-4 (American Type Culture Collection, Manassas, VA, USA),
Capan-1, PaCa3, SK-PC 1, PANC-2, PC (generous gift from
Professor A Scarpa, University of Verona, Verona, Italy) were
cultured as monolayers in RPMI 1640 (Biochrom, Berlin,
Germany), supplemented with 10% heat-inactivated FCS (Hyclone,
Logan, UT, USA), penicillin and streptomycin (100mgml
 1) under
standard culture conditions (5% CO2, 95% air in humidified
chamber at 371C). Cells were cultivated in 72cm
2 flasks (Costar,
Cambridge, MA, USA) and were harvested with trypsin when they
were in logarithmic growth.
Cell cycle, apoptosis analysis, clonogeneic capacity
Cells were plated in 24-well sterile plastic plates (Costar) at
15 10
4 cellml
 1 and were allowed to attach for 24h. Then, cells
were treated with different concentration (0.001–100mM) and
combination of GEM, 5-FU, DCT, OXP, CPT-11, PMX and RTX for
48h. After drug treatment, cells were trypsinised, washed once
with PBS, and fixed with 70% ethanol at  201C for 24h. Fixed cells
were washed three times and stained with a propidium iodide (PI;
Sigma Chemical Co., St Louis, MO, USA) solution (20mgml
 1)
containing 0.1mgml
 1 of RNase A (Sigma Chemical Co., St Louis,
MO, USA). Cells were then subjected to cell cycle analysis for
determining DNA contents by flow cytometry (FACScan, Cell
Quest software; BD Biosciences, San Jose, CA, USA). Cell debris
was excluded on the basis of forward vs side scatter. Doublets and
clumps were excluded by gating on a bivariate distribution of AUX
(PI peak pulse) vs the PI-integrated signal. Data from 10000 events
were collected in the final gated histograms. Apoptotic cells were
identified on the basis of hypodiploid DNA content (subG1
fraction) that results from DNA fragmentation and confirmed
with the evaluation of phosphatidylserine exposure using annexin
V-FITC Kit (Bender MedSystems, San Bruno, CA, USA) in
combination with PI.
The activation of caspase 3/7 was analysed after drug treatment
using Carboxyfluorescein FLICA Assay Kits (B-Bridge Interna-
tional, Inc., Sunnyvale, CA, USA) according to the manufacturer’s
instructions.
For the clonogenicity assay, cells were exposed for 48h to the
drug; then cells were washed, plated by limiting dilution down to
three cell per well and cultured with drug-free fresh medium. After
1 week, each well was checked by optical microscopy for growing
colonies (at least four cells per well).
The IC50 was defined as the drug concentration required to
induce 50% of apoptotic cells and was calculated by nonlinear
least-square curve fitting. Drug interaction was assessed at
different concentration ratio (0.1:1; 1:1; 10:1) using the
combination index (CI; Chou et al, 1994), where CIo1, CI¼1
and CI41 indicate synergistic, additive and antagonistic effects,
respectively.
Since several preclinical studies have shown a schedule-
dependent drug interaction for the antimetabolites in combination
regimens (Tolis et al, 1999; van Moorsel et al, 1999; Peters et al,
2000; Edelman et al, 2001; Symon et al, 2002; Giovannetti et al,
2004), we tested, in vitro, different treatment schedules. For the
experiments of sequential exposure, cells were treated with (a)
drug 1 (0.001–100mM) for 48h; (b) drug 2 (0.001–100mM) for 48h;
(c) drug 1 together with drug 2 (0.001–100mM, ratio 1:1) for 48h;
(d) drug 1 (0.001–100mM) for 24h followed by drug 2 for 24h
(ratio1:1); (e) the reverse sequence of point (d). On the basis of
the isobologram analysis for mutually exclusive effects, the CI
value was calculated as follows:
CI ¼ð DÞ1=ðDxÞ1 þð DÞ2=ðDxÞ2
where (Dx)1 and (Dx)2 are the concentrations of the single drugs
required to induce cell apoptosis by 50%, and (D)1 and (D)2 are the
drug concentrations in combination treatments which also induce
cell apoptosis by 50% (isoeffective as compared with single drugs).
In some experiments, a nonconstant ratio combination design was
used and the CI value for each data point was calculated. Data
analysis was performed by the Calcusyn Software (Biosoft, Oxford,
UK).
In vivo study
MIA PaCa2, CFPAC-1 and PaCa3 cells (5 10
6 cells for each mice)
were s.c. injected into female nude mice (4 weeks of age, Harlan,
Italy). One week after cell inoculation (day 0), five randomised
animals for each experimental group received GEM (150mgkg
 1
i.p.) at day 0, þ3, þ6, þ9, þ12, þ15, þ18 and þ21 or GEM
(150mgkg
 1 i.p.) at day 0, þ3, þ6 and þ9 and then PMX
(100mgkg
 1 i.p.) every day starting from day þ12 until day þ21
plus CPT-11 (50mgkg
 1 i.p.) at day þ12 and þ17. Control group
received only the vehicle (PBS i.p.) at the same time. Tumour
volume and body weight were daily recorded for each animal for
all the period of drug treatments (day 0–21) and for 10 days after
treatment suspension (days 22–32). Tumour volume was calcu-
lated using the formula: V¼p/6 (largest diameter smallest
diameter)
3/2. The ethical standards of the experiment were
approved by the Verona University Review Board, and the animals
were maintained in accordance with institutional guidelines.
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Data were expressed as mean values þs.d. or median (25–751
percentiles). Differences between the IC50 were analysed by
Wilcoxon Signed Ranks test. The potential of drugs for inhibition
of in vivo tumour growth was analysed using Tukey’s HSD test.
Statistical analyses were performed using the Statistical Package
for Social Science (SPSS 11.0; SPSS, Chicago, IL, USA).
RESULTS
Induction of apoptosis by GEM, 5-FU, DCT, OXP, CPT-11,
PMX and RTX in pancreatic cancer cell lines: a
comparative evaluation in relation with the ‘in vivo’
plasma maximum concentration (Cmax) of the single drugs
MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines
were treated with GEM, fluouracil (5-FU), docetaxel (DCT),
oxaliplatin (OXP), irinotecan (CPT-11), pemetrexed (PMX) and
raltitrexed (RTX) as single agent. The efficacy of the drugs was
evaluated considering the 50% induction apoptosis concentration
(IC50) in relation with the Cmax (Figure 1). The majority of the
IC50s measured resulted abundantly over the Cmaxs of the drugs,
confirming pancreatic cancer as a chemoresistant tumour. A dose-
dependent induction of apoptosis with IC50 under the Cmax in all
the three lines tested was observed only by using PMX (Cmax
229mM; median IC50: 67.16, 2.54 and 27.12mM, respectively, for
MIA-PaCa2, CFPAC-1 and Capan-1; n¼12). Two lines of three
showed IC50 under Cmax in the presence of DCT (Cmax 0.99mM;
median IC50: 0.48, 0.1147 and 8109mM, respectively, for MIA-
PaCa2, CFPAC-1 and Capan-1; n¼12). One line of three showed
IC50 under Cmax in the presence of RTX (Cmax 1.54mM; median
IC50: 27.77, 7.37 and 0.86mM, respectively, for MIA-PaCa2, CFPAC-
1 and Capan-1; n¼12), OXP (Cmax 2.05mM; median IC50: 312, 0.57
and 6.58mM, respectively, for MIA-PaCa2, CFPAC-1 and Capan-1;
n¼12), GEM (Cmax 61mM; median IC50: 2.49, 72.48 and 559mM,
respectively, for MIA-PaCa2, CFPAC-1 and Capan-1; n¼12) and
5-FU (Cmax 372mM; median IC50: 26.19, 410000 and 1750mM,
respectively, for MIA-PaCa2, CFPAC-1 and Capan-1; n¼12).
Finally, no lines showed IC50 under Cmax in the presence of CPT-11
(Cmax 16.05mM; median IC50: 25.64, 232 and 30.33mM, respectively,
for MIA-PaCa2, CFPAC-1 and Capan-1; n¼12).
Study of PMX/GEM, PMX/DCT and PMX/CPT-11
combination
We chose PMX as the drug to be tested in combination studies,
since it appeared the most efficient drug in inducing apoptosis as
single agent. We assessed the interaction of PMX with GEM
(antimetabolite), DCT (antimicrotubule agent) and CPT-11
(topoisomerase inhibitors) in a constant ratio combination
experimental design. We used three different concentration ratios
for the study (10:1; 1:1; 0.1:1).
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Figure 1 Drug concentrations required to induce the 50% apoptotic
cells (IC50) in culture. MIA PaCa2, CFPAC-1 and Capan-1 pancreatic
cancer cell lines were treated with gemcitabine (GEM), fluorouracil (5-FU),
docetaxel (DCT), oxaliplatin (OXP), irinotecan (CPT-11), pemetrexed
(PMX) and raltitrexed (RTX) for 48h with different concentration (0.001–
100mM). Data are expressed as median of 12 experiments. The plasma
maximum concentration of the drugs (Cmax) as described by human
pharmacokinetics studies (Abbruzzese et al, 1991; Burris et al, 1993; Extra
et al, 1993; Pazdur et al, 1993; Rothenberg et al, 1993; Clarke et al, 1996;
Chabot, 1997; Hui and Reitz, 1997; Beale et al, 1998; Gamelin et al, 1998;
Judson et al, 1998; O’Dwyer et al, 1999; Rinaldi, 1999; Culy et al, 2000;
Jodrell et al, 2001) was also reported. Red colour-filled symbol: IC504Cmax;
green colour-filled symbol: IC50o Cmax.
1
1
100
+
+1 1
11
Capan-1
1
1
MIA PaCa 2 CFPAC-1
PMX Cmax
GEM Cmax
PMX Cmax
DCT Cmax
PMX Cmax
CPT-11 Cmax
1000
10
0.1
0.01
PMX
GEM
10
10
+
+1 1
11
1
1 PMX
DCT
10
10
+
+1 1
11
1
1 PMX
CPT-11
10
10
I
C
5
0
 
(

M
)
100
1000
10
0.1
0.01
I
C
5
0
 
(

M
)
1
100
1000
10
0.1
0.01
I
C
5
0
 
(

M
)
Figure 2 The IC50s( mM) of PMX–GEM, PMX–DCT and PMX–CPT-
11 combinations. The 10:1, 1:1 and 1:10 concentration ratio of PMX/
GEM, PMX/DCT and PMX/CPT-11 combinations were represented.
Moreover, MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines
were treated with (a) PMX together with GEM, DCT or CPT-11 (0.001–
100mM, ratio 1:1) for 48h; (b) PMX (0.001–100mM) for 24h followed by
GEM, DCT or CPT-11 for 24h (ratio1:1); (c) the reverse sequence of
point (b). The IC50 values of the different ratio and sequences were
calculated and reported. All the values are expressed as medians of six
experiments. Black colour-filled symbol¼IC50 significantly less than the
IC50s of the single drug (Po0.05, Wilcoxon Signed Ranks test). Grey
colour-filled symbol¼IC50 significantly less than the IC50 of the
simultaneous exposure for 48h (Po0.05, Wilcoxon Signed Ranks test).
Dotted lines: Cmax of GEM, DCT, CPT-11 and PMX.
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most efficient combination in inducing apoptosis with IC50 less
than the IC50s of the single drugs in all the lines tested (Figure 2).
The effect appeared particularly strong at the 10:1 ratio (but it is
also present at 1:1 and 1:10 ratio) and the calculation of the CI
showed synergism at effect levels obtainable with concentration
under the Cmax of CPT-11 and PMX (Figure 3).
The PMX–GEM combination appeared efficient in inducing
apoptosis (IC50 less than the IC50 of the single drugs) in two of
three lines tested at the 10:1 ratio concentration (Figure 2), and
the CI values at the same ratio showed synergism at concentrations
under the Cmax of GEM and PMX (Figure 2). At 1:1 ratio
concentration, an additive (MIA PaCa2, Capan-1) or antagonistic
(CFPAC-1) effect was present (Figure 3).
Finally, the effect of DCT in combination with PMX was variable
and cell line dependent (Figures 2 and 3). CFPAC-1 cell line
appeared sensitive to the action of DCT–PMX combination (IC50
less than the IC50s of the single drugs at 10:1 and 1:1 ratios tested
and strong synergism both at 10:1 and 1:1 ratios), while, on the
contrary, Capan-1 appeared resistant (no reduction of IC50s at any
ratio tested and CI indicating substantially an antagonism). MIA
PaCa2 cell line showed an intermediate level of sensitivity.
The interaction of PMX with GEM, DCT and CPT-11 was also
tested in a nonconstant ratio combination design varying the
concentrations of each drug from 0.01 to 10mM. As long as the
shape of the dose–effect curve and the median effect dose
parameters for each single drug are available, the CI values for
each data point of the nonconstant ratio design were calculated
(Chou et al, 1994). The nonconstant ratio combination experi-
ments confirmed the results of the constant ratio experiments and
in particular the strong synergistic effect of PMX and CPT-11 in all
the lines tested (Figure 4).
Study of the schedule-dependent activity of PMX–GEM,
PMX–DCT and PMX–CPT-11 combination
Cell lines were treated with (a) PMX together with GEM, DCT or
CPT-11 (0.001–100mM, ratio 1:1) for 48h; (b) PMX (0.001–
100mM) for 24h followed by GEM, DCT or CPT-11 for 24h
(ratio1:1); (c) the reverse sequence of point (b). The IC50 and CI
values of the different sequences were calculated (Figures 2 and 5).
The sequential exposure to PMX followed by GEM (PMX-
GEM) appeared more efficient in inducing apoptosis than the
reverse sequence (GEM-PMX) in CFPAC-1 and MIA PaCa2 lines,
while this schedule of treatment appeared substantially indifferent
in Capan-1 line (Figure 2). The CI calculation confirmed in
CFPAC-1 line the synergism for PMX-GEM sequence at effect
level obtainable with concentration under the Cmax of GEM, while
the GEM-PMX sequence produced antagonism in all the lines
tested (Figure 5).
For the PMX–DCT combination, DCT followed by PMX
(DCT-PMX) was more efficient in inducing apoptosis than the
reverse sequence (PMX-DCT). DCT-PMX sequence reduced
the IC50 under the level of simultaneous exposure in Capan-1 and
MIA PaCa2 lines, while it did not induce any substantial
modification in CFPAC-1 line (Figure 2). In Capan-1 and MIA
PaCa2 lines, the calculation of CI value confirmed the synergism
for DCT-PMX sequences (Figure 5).
Finally, the sequential exposure to PMX followed by CPT-11
(PMX-CPT-11) appeared more efficient than the reverse
sequence (CPT-11-PMX) in inducing apoptosis in all the lines,
but the IC50 values of the PMX-CPT-11 sequence were higher
than those of the simultaneous exposure (Figure 2). Moreover,
the calculation of the CI value at effect level obtainable with
concentration under the Cmax of CPT-11 showed antagonism for
both the PMX-CPT-11 and CPT-11-PMX sequences in all the
lines (Figure 5). These data suggested that for the PMX–CPT-11
combination, the sequential exposure to the drugs does not
improve the action in comparison to the simultaneous exposure.
Study of the PMX–CPT-11 combination activity on a large
panel of pancreatic cancer cell lines: effect on cell survival,
cell cycle, clonogenicity, caspases 3–7 activation
To confirm the efficacy of PMX–CPT-11 combination, we
extended the study to a larger panel of pancreatic cancer cell lines
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Figure 3 Combination index (CI) plots of PMX/GEM, PMX/DCT and PMX/CPT-11 association in MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer
cell lines. Data are represented as concentration/combination index (CI) plot. The CI was calculated in a constant ratio combination experimental design.
The 1:1 and 10:1 concentration ratio of PMX/GEM, PMX/DCT and PMX/CPT-11 combinations were represented. CIo1 (green colour), CI¼1 and
CI41(red colour) indicate synergistic, additive and antagonistic effects, respectively. Dotted lines: Cmax of GEM, DCT, CPT-11 and PMX. The plots represent
the mean of six experiments.
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lines (PaCa3, SK-PC 1, PANC-2, MiaPaCa-2 from primary cancer;
CFPAC1, PC, HS766T, Capan-1, T3M4, from metastases; A818-4
from ascites) were treated with the PMX (10mM)/CPT-11(1mM)
combination for 48h. Cell recovery, viability and apoptosis (cell
cycle and caspase 3/7 activation) were analysed. In eight of 10
lines, PMX/CPT-11 significantly reduced cell recovery and
increased both the subG1 and caspase 3/7 fraction (Table 1).
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Figure 5 Combination index (CI) plots of schedule-dependent PMX/GEM, PMX/DCT and PMX/CPT-11 combination in MIA PaCa2, CFPAC-1 and
Capan-1 pancreatic cancer cell lines. Cell lines were treated with (a) PMX (0.001–100mM) for 24h followed by GEM, DCT or CPT-11 for 24h at 1:1 ratio
(white symbols); (b) the reverse sequence of point (a) (grey symbols). CIo1 (green colour), CI¼1 and CI41 (red colour) indicate synergistic, additive and
antagonistic effects, respectively. The data represent the mean of three experiments. Dotted lines: fraction affected at Cmax of different drug for each line
tested.
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phases during the treatment and that have lost the capacity to
reproduce, after the 48h drug exposure, the pancreatic cancer cell
lines were washed and cultured in a drug-free environment for 5
days. After the wash out period, an increased fraction of subG1 and
caspase 3/7 persisted in PMX–CPT-11-pretreated cell lines.
Moreover, a significant reduction in the clonogenicity capacity of
the lines was evident (Table 2).
In vivo antitumour effect of PMX–CPT-11 combination
after GEM treatment in xenografted nude mice
To evaluate the in vivo antitumour effect of PMX–CPT-11
combination as second-line salvage chemotherapy, CFPAC-1,
MIA PaCa2 and PACA3 xenograft tumours established subcuta-
neously in athymic nude mice were treated with vehicle (PBS) or
GEM (days 0–12). Starting from day þ12, the GEM-treated
tumours were randomised to be treated with PMX/CPT-11 (day
12–22) or with GEM (days 12–22) (Figure 6). The growth of
CFPAC-1 xenografts was completely abolished by i.p. injection of
GEM. In detail, at 12 days, the mean volumes were 32724 and
29711mm
3 in the two groups receiving GEM, which were
significantly smaller than that in control group (5167133mm
3;
Po0.001). The shift of the treatment to PMX/CPT-11 did not
change the growth of CFPAC-1 in comparison to GEM. At 22 days,
the mean volumes were 573 and 20715mm
3, respectively, in
groups receiving GEM or PMX–CPT-11 (P¼0.89), which re-
mained significantly smaller than that in control group
(13047458mm
3; Po0.001). The inhibition of the growth was
maintained even after drug withdrawn. The growth of MIA PaCa2
xenografts was significantly inhibited, but not completely abol-
ished by i.p. injection of GEM. In detail, at 12 days, the mean
volumes were 194792 and 178729mm
3 in the two groups
receiving GEM, which were significantly smaller than that in
control group (4687151mm
3; Po0.01). The shift to the PMX/
CPT-11 was more effective in inhibiting the growth of MIA PaCa2
than the maintenance of GEM treatment. At 22 days, the mean
volumes were 3157135 and 138733mm
3, respectively, in groups
receiving GEM or PMX–CPT-11 (P¼0.05) and both remained
significantly smaller than that in control group (11227334mm
3;
Po0.001). Also in MIA PaCa2 xenografts, the effect on the growth
was maintained even after drug withdrawn. Similarly to MIA
PaCa2 xenografts, PACA3 xenografts showed a partial sensibility to
the GEM action and an increased inhibition of growth after the
shift to the PMX/CPT-11 treatment. At 12 days, the mean volumes
were 8667273 and 7707216mm
3 in the two groups receiving
GEM, which were significantly smaller than that in control group
(16107445mm
3; Po0.05). At 22 days, the mean volumes were
13227440 and 7987171mm
3, respectively, in groups receiving
GEM or PMX–CPT-11 (P¼0.05) and both remained significantly
smaller than that in control group (21477463mm
3; Po0.01).
DISCUSSION
The aim of the present study was to identify in vitro new drug
combinations to be used in clinical testing as salvage chemotherapy
Table 1 Effect of PMX:CPT-11 combination on cell recovery, cell cycle, caspase 3/7 activation: 48h exposure
Cell recovery Cell cycle (%)
Cell line
a Source
b PMX–CPT-11 Cell number ( 10
6) % % Caspase 3/7
+ SubG1 G1 S G2 Hyper G2 G2/G1
MIAPaCa2 P   0.88 1.6 30 53 4 8 5 1.45
+ 0.68 77 2.9 51 27 11 7 4 0.27
PaCa3 P   1.7 6.9 17 60 3 14 7 0.23
+ 2.0 113 6.9 10 64 6 15 6 0.23
SK-PC 1 P   0.47 13 29 52 4 12 4 0.22
+ 0.23 50 18 47 27 11 11 5 0.41
PANC-2 P   1.95 8.9 4 51 15 23 9 0.45
+ 0.58 30 61.5 13 28 14 24 23 0.88
CFPAC1 M   0.56 19.8 19 34 3 17 28 0.49
+ 0.37 65 34.38 27 32 4 15 21 0.46
PC M   1.17 24.8 6 39 5 28 22 0.72
+ 0.56 48 39.9 10 24 18 2 25 0.99
HS766T M   0.23 37.4 24 39 7 17 15 0.43
+ 0.17 71 45.6 39 36 5 13 8 0.35
Capan-1 M   0.42 7.2 65 19 2 7 7 0.39
+ 0.25 60 5 71 11 5 6 6 0.53
T3M4 M   0.93 45 22 29 4 15 29 0.52
+ 0.49 53 61 50 27 6 7 10 0.26
A818-4 A   0.63 7.3 4 22 1 31 41 1.36
+ 0.70 111 11.8 8 22 8 27 37 1.20
Median   0.76 10.9 20.61 38.7 3.9 15.7 11.8 0.47
+ 0.52 26.1 33.11 27.2 6.7 13.7 8.9 0.43
P
c 0.047 0.017 0.017 0.022 0.017 0.047 NS NS
aData reported are the mean of two experiments for each cell line.
bP¼primary tumour; M¼liver or lymph nodes metastasis; A¼ascites.
cWilcoxon Signed Rank test; NS¼not
statistically different. PMX¼pemetrexed; CPT-11¼irinotecan.
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sin pancreatic cancer patients after GEM failure. The PMX and
CPT-11 combination showed the strongest schedule-independent
synergistic cytotoxic activity. Its efficacy was confirmed in vitro in
a large panel of pancreatic cancer cell lines using clinically relevant
concentrations and in vivo in three xenograft tumours providing
experimental basis for its clinical testing as salvage chemotherapy
in pancreatic cancer patients.
Pemetrexed inhibits thymidylate synthase, dihydrofolate reduc-
tase, and glycinamide ribonucleotide formyltransferase (Shih et al,
1997), thereby depleting nucleotide pools and blocking DNA
synthesis (Tonkinson et al, 1997; Chen et al, 1999). Single-agent
PMX in vivo has demonstrated activity in pancreatic cancer with a
response rate of 5.7%, median survival of 6.5 months and 1-year
survival of 28%, as reported in a phase II study (Miller et al, 2000;
Kindler, 2002). On the basis of these data, together with phase I
data showing synergy between GEM and PMX in a broad range of
tumours, a phase III study of GEM/PMX combination was
conducted on pancreatic cancer patients (Kindler, 2002; Oettle
et al, 2005). Unfortunately, the results showed that the combina-
tion of PMX and GEM did not improve survival in patients with
unresectable locally advanced or metastatic pancreatic cancer with
an increase in toxicity compared with GEM monotherapy, but
other combinations of PMX should continue to be explored in an
effort to further improve the treatment of this chemorefractory
disease.
Based on the PMX activity as single agent, we tested PMX in
combination with DCT (antimicrotubule agent) and CPT-11
(topoisomerase inhibitors). The combinations of PMX with OXP
or RTX were not assessed because a phase II clinical trial with RTX
and OXP as salvage chemotherapy in GEM-resistant metastatic
pancreatic cancer was already concluded and the results were
recently reported (Reni et al, 2006). The in vitro study clearly
indicates the PMX and CPT-11 combination as the most active one
against pancreatic cancer: (i) the PMX and CPT-11 combination
strongly reduced the IC50 in all the three lines tested; (ii) the effect
was relevant at concentration that it is possible to achieve in vivo;
(iii) the effect was maximum for the relevant clinical concentration
ratio of 10:1. (iv) the sequential exposure PMX-CPT-11
appeared more efficient than the reverse sequence CPT-11-
PMX, but the IC50 values of the PMX-CPT-11 sequence remained
higher than those of the simultaneous exposure.
The efficacy of PMX–CPT-11 combination was confirmed in a
panel of 10 pancreatic cancer cell lines using clinically relevant
concentrations (PMX 10mM; CPT-11 1mm). Based on the data
obtained in vitro, we also tested the efficacy PMX/CPT-11
combination in vivo in CFPAC-1, MIA PaCa2 and PACA3
xenograft tumours established subcutaneously in athymic nude
mice. Since the objective was to provide experimental basis for use
in clinical trial as second-line salvage chemotherapy, we design
to treat mice with PMX/CPT-11 after the GEM therapy and not
as first-line therapy. Pemetrexed/CPT-11 combination showed
the ability to further inhibit the cancer growth in the two lines
partially responsive to GEM and to maintain the block of
proliferation in the GEM full responsive line. Even if the in vivo
Table 2 Effect of PMX:CPT-11 combination on cell recovery, cell cycle, caspase 3/7 activation and clonogenicity: 5 days after 48h exposure
Cell recovery Cell cycle (%)
Cell line
a Source
b PMX–CPT-11
Cell number
( 10
6) % %Caspase 3/7
+ SubG1 G1 S G2 Hyper G2 G2/G1
Clonogenicity
(clone number)
MIAPaCa2 P   0.56 1 27 51 6 11 6 0.22 5.25
+ 0.52 94 4.5 37 57 3 3 0 0.05 2
PaCa3 P   0.68 7.1 9 54 10 23 5 0.43 9.3
+ 0.76 111 16.9 20 31 11 27 11 0.88 7.9
SK-PC 1 P   0.22 0.8 15 57 9 12 8 0.21 2.5
+ 0.1 44 2.5 54 12 23 6 6 0.54 1.25
PANC-2 P   1.02 32 7 44 17 22 12 0.50 13
+ 0.08 8 57.7 55 8 12 10 14 1.18 2.5
CFPAC1 M   0.30 34.7 20 36 7 21 17 0.60 2.75
+ 0.19 56 31.8 47 10 11 19 13 1.96 1.31
PC M   0.20 0.8 4 54 5 22 15 0.41 7.5
+ 0.10 50 7.4 15 13 25 24 25 1.85 3.5
HS766T M   0.25 1.8 7 46 8 19 20 0.41 4.75
+ 0.15 60 7.6 16 19 23 18 25 0.95 1.25
Capan-1 M   0.12 3.7 59 21 5 8 7 0.36 4.25
+ 0.07 57 17.6 88 7 2 1 1 0.19 1.75
T3M4 M   0.45 15 16 40 2 17 24 0.43 3.75
+ 0.05 12 31 84 11 1 2 1 0.18 1
A818-4 A   0.24 8 6 47 13 23 10 0.49 4.25
+ 0.14 58 15 13 20 30 29 9 1.45 1.75
Median   0.28 5.4 11.6 46.7 7.7 20.2 10.8 0.41 4.5
+ 0.1 15.9 41.9 12.3 11.8 14.2 9.8 0.91 1.75
P
c 0.009 0.005 0.005 0.007 NS NS NS 0.028 0.005
aData reported are the mean of two experiments for each cell line.
bP¼primary tumour; M¼liver or lymph nodes metastasis; A¼ascites.
cWilcoxon Signed Rank test; NS¼not
statistically different. PMX¼pemetrexed; CPT-11¼irinotecan.
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sresults of PMX/CPT-11 treatment could appear quantitatively
disappointing, starting from the presence of GEM pretreatment,
they should be considered relevant.
The PMX/CPT-11 combination respects the four principles
underlying the design of chemotherapy combination. First,
each agent in a regimen has shown to be independently active
against the pancreatic tumour. In fact, not only PMX, as above
reported, has demonstrated to be active as single agent but CPT-11
also has demonstrated activity, although modest, in pancreatic
cancer (Wagener et al, 1995; Klapdor and Fenner, 2000; Pizzolato
and Saltz, 2003). Unfortunately, a recently reported phase III
trial of GEM with or without CPT-11 revealed no survival
benefit (Rocha Lima et al, 2004; Stathopoulos et al, 2006) but
other combinations of CPT-11 should continue to be explored
in an effort to further improve the treatment of this chemo-
refractory disease (Taieb et al, 2006). Secondly, each drug in this
combination has an independent mechanism of action. In fact,
PMX is an antimetabolite while CPT-11 is a selective DNA
topoisomerase I inhibitor, targeting different steps along
different biochemical pathways. Pavillard et al (1998) have
shown an inverse relationship between thymidylate synthase
activity and irinotecan-induced cleavable complex formation,
which suggests a potential mechanism whereby synergy between
PMX and CPT-11 might be expected to occur. Third, there is no
crossresistance, at least in vitro, between PMX and CPT-11 and
also among these two drugs and GEM. Fourth, PMX and CPT-11
have a different dose-limiting toxicity. Both the susceptibility to
PMX/CPT-11 combination even in GEM-resistant lines and the
evidence from previous works that in vivo full doses of PMX and
CPT-11 are well tolerated in several small phase I and II trials in
pretreated colorectal cancer patients (Grothey and Schmoll, 2001;
Rowinsky et al, 2007) encourage the use of these two drugs in
clinical experimental protocols as second-line treatment for
pancreatic cancer.
In our study we also reported the evaluation of PMX combined
with GEM, even if we looked for GEM-free protocol. The
reason was that this combination represents a sort of reference
point, since preclinical and clinical studies have shown synergy
in a broad range of tumours including pancreatic cancer (Adjei
et al, 2000; Giovannetti et al, 2004; Dy et al, 2005; Oettle et al,
2005). Consequently, the evidence of a major efficiency of the
PMX–CPT-11 in comparison with the PMX–GEM should be
considered as a further reason for its clinical testing. Of note, the
phase III clinical study of PMX–GEM combination showed
that the use of GEM intravenously over B30min followed
B90min later by PMX does not improve survival in patients
with unresectable locally advanced or metastatic pancreatic
cancer (Kindler, 2002; Oettle et al, 2005). The absence of preclinical
data of PMX–GEM combination specifically on pancreatic
cancer was probably one of the cause of the failure of the phase
III study. In fact, the use of the sequence was based on studies
demonstrating synergistic cytotoxicity when GEM exposure
precedes PMX exposure in HCT-8-cultured human colon cancer
cell lines (Adjei et al, 2000) and on similar results obtained in
LoVo, WiDr and LRWZ cells (Tesei et al, 2002). However, other
reports proposed synergistic cytotoxicity for the opposite sequence
PMX exposure followed 24h later by GEM exposure (Tonkinson
et al, 1999; Giovannetti et al, 2004). Our study suggested that the
highest chemotherapeutic activity against MIA PaCa-2, PANC-1
and Capan-1 cells for PMX–GEM combination is observed with
the sequence PMX-GEM, exactly the opposite of that used in
clinical trial. Since the patterns of interaction with these two agents
is cell line and tissue specific, the limited availability of preclinical
data on PMX–GEM combination on pancreatic cancer likely
hampered the rational design of the clinical study contributing to
its failure.
To date, different options based on GEM are available for first-
line treatment of pancreatic cancer (Burris et al, 1997; Reni et al,
2005). However, GEM-based chemotherapy yields a very limited
disease control, and progression usually occurs within a few
months after first-line treatment starts. In spite of progressive
disease, about half of the patients maintain a good performance
status and are willing to undergo further treatment. As no standard
therapeutic option exists and scarce information on the impact on
outcome of salvage therapy is available from the literature, studies
attempting to widen the therapeutic armamentarium against this
disease are warranted. Based on the result of our study, the PMX/
CPT-11 association appears a promising GEM-free drug combina-
tion and we think that our results provide the experimental basis
for its clinical testing as salvage chemotherapy in pancreatic cancer
patients.
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Figure 6 Antitumour activity of PMX/CPT-11 combination against
pancreatic cancer xenografts. MIA PaCa2, CFPAC-1 and PACA3 xenograft
tumours established subcutaneously in athymic nude mice were rando-
mised to treatment groups (n¼5 mice pergroup). The treatment groups
were untreated controls (black symbol: PBS i.p.), GEM alone (white symbol:
150mgkg
 1 i.p. on days 0, þ3, þ6, þ9, þ12, þ15, þ18, þ21) or
PMX/CPT-11 after GEM treatment (grey symbol: GEM 150mgkg
 1 i.p. on
days 0, þ3, þ6, þ9; PMX 100mgkg
 1 i.p. on every day starting from day
þ12 until day þ21; CPT-11 50mgkg
 1 i.p. on days þ12 and þ17) Data
are expressed as the median change (fold increase) in tumour volume
relative to volume on day 0, when treatment was initiated (MIA
PaCa2¼89.288mm
3; CFPAC-1¼65.46mm
3; PACA3¼261.87mm
3).
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